FSD Pharma files application to begin Phase 2 trial of FSD-201 in U.S. and Canada
JHVEPhoto/iStock Editorial via Getty Images
- FSD Pharma (NASDAQ:HUGE) said on Tuesday it had submitted an application to the U.S. Food and Drug Administration and Health Canada to begin Phase 2 trial of FSD-201 to treat a yet-to-be-disclosed inflammatory disorder.
- FSD Pharma holds exclusive worldwide (excluding Italy and Spain) licensing rights to FSD-201 for all conditions in all regulatory categories.
- FSD-201 is expected to be in the mid-stage trials in Q3.
- Also read - FSD Pharma closes sale of cannabis facility for C$16.4M, to focus on biotech business.
- (HUGE -5.9%)